Pharsight

Eliquis patents expiration

ELIQUIS's oppositions filed in EPO
ELIQUIS Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6967208 BRISTOL MYERS SQUIBB Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
Nov, 2026

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326945 BRISTOL MYERS SQUIBB Apixaban formulations
Feb, 2031

(7 years from now)

Eliquis is owned by Bristol Myers Squibb.

Eliquis contains Apixaban.

Eliquis has a total of 2 drug patents out of which 0 drug patents have expired.

Eliquis was authorised for market use on 28 December, 2012.

Eliquis is available in tablet;oral dosage forms.

Eliquis can be used as prophylaxis of deep vein thrombosis and pulmonary embolism; reducing the risk of stroke and systemic embolism; treatment of pulmonary embolism (pe); reduce the risk of recurrent deep vein thrombosis (dvt); treatment of deep vein thrombosis (dvt); reduce the risk of recurrent pulmonary embolism; prophylaxis of deep vein thrombosis (dvt); reducing the risk of stroke; prophylaxis of pulmonary embolism.

The generics of Eliquis are possible to be released after 24 February, 2031.

Drugs and Companies using APIXABAN ingredient

Market Authorisation Date: 28 December, 2012

Treatment: Prophylaxis of deep vein thrombosis and pulmonary embolism; Reducing the risk of stroke and systemic embolism; Treatment of pulmonary embolism (pe); Reduce the risk of recurrent deep vein thrombosis (...

Dosage: TABLET;ORAL

How can I launch a generic of ELIQUIS before it's drug patent expiration?
More Information on Dosage

ELIQUIS family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic